Danaher Life Sciences eSeminar - Latest Trends in Precision Medicine
The goal of precision medicine is to deliver the right treatment at the right time to the right patient. To achieve better-tailored medicine, therapies must be developed not for the average person (the aggregate population) but with consideration of the varied nature of the individual and their disease.
This eSeminar, “Latest Trends in Precision Medicine,” will bring together Beckman Coulter Life Sciences, Leica Microsystem, Leica Biosystems, Phenomenex, Pall Corporation, Integrated DNA Technologies, and SCIEX, all from Danaher’s Life Sciences division, plus Beckman Coulter Diagnostics, to share the latest innovations and tools for precision medicines that accelerate your research.
Phenomenex 09:25 - 09:30 : Welcome (Sueki Leung, Regional Marketing Manager)
Danaher 09:30 - 09:40 : Introduction to Danaher (Siong Teck Chew, VP Commercial Management)
Integrated DNA Technologies 9:40 - 10:00 : Next Generation Sequencing Applications for Research (Simon Dunbar. NGS Sales Manager, APAC)
SCIEX 10:00 - 10:20 : Confirming Gene Mutation by CRISPR-Cas9 at Protein Level and Proteome Changes Using SWATH® Acquisition (Justin Lim, PhD, Senior Advanced Workflow Specialist Omics)
Beckman Coulter 10:20 - 10:40 : Characterizing Viruses – From Deadly Pathogens to the Workhorses of Gene Therapy (Akash Bhattacharya, PhD, Senior Application Scientist)
Molecular Devices 10:40 - 11:00 : Automated Solutions for Drug Screening in 3D Spheroid and Organoid Models (Minho Tak, PhD, JAPAC BioPharma Application Scientist)
Leica Microsystem 11:00 - 11:20 : Understanding Multiscale Tumor Heterogeneity with Hyperplex Biomarker Imaging at Single Cell Level (Hui Yee Chua, PhD, Application Specialist)
Cytiva 11:20 - 11:40 : Cell and Gene Therapy – Your Path Forward (Mandy Cheng, PhD, ES FastTrak Technical)
Pall Corporation 11:40 - 12:00 : Pall Laboratory Portfolio Supporting Gene Therapy for Precision Medicine Research (Chuthakorn Chartthai, Technical Specialist)
Phenomenex 12:00 - 12:20 : Expanding the Capabilities of Micro-UHPLC for mAb Therapeutics (Zachary Woodward, Technical Specialist)
